Select Off-Label Compounded Ketamine Options
In select cases, Meadowlark Mind & Body may consider off-label compounded ketamine as part of a carefully monitored treatment plan. This is not promoted as a first-line or main treatment option and is not appropriate for every patient.
Off-label compounded ketamine may be considered only after clinical evaluation and a thorough discussion of risks, benefits, alternatives, limitations, safety concerns, abuse potential, dissociation, sedation, blood pressure effects, and monitoring expectations.
How We Frame Ketamine Care
- Considered only after careful clinical evaluation.
- Not a first-line treatment; not a substitute for standard psychiatric care.
- Risks, benefits, alternatives, and limitations are reviewed in detail.
- Informed consent is required.
- Monitoring expectations are clearly defined.
- Patients experiencing suicidal intent, psychosis, mania, severe intoxication, substance misuse concerns, or medical instability may require a higher level of care or emergency evaluation.
Why We Are Careful With Compounded Ketamine
Ketamine may be helpful for select patients, but it requires careful screening, dosing boundaries, monitoring, and safety planning. Meadowlark Mind & Body does not use compounded ketamine as a casual wellness product, a first-line treatment, or a substitute for standard psychiatric care. When considered, it is part of a monitored psychiatric treatment plan with informed consent.
We do not prescribe compounded ketamine to: patients with active suicidal ideation requiring emergency intervention, active psychosis, mania, severe untreated substance use disorder, significant cardiovascular instability, or patients who are seeking ketamine as a primary or stand-alone treatment without engaging in appropriate psychiatric care.
Related: Spravato
For appropriate adults with treatment-resistant depression, Spravato® is an FDA-approved esketamine nasal spray that may be discussed as a treatment option. Spravato requires in-office administration and monitoring, and MMB follows applicable Spravato REMS safety requirements.
Ketamine and Spravato Safety Disclaimer
Spravato® is only available after an appropriate clinical evaluation and is not appropriate for every patient. Treatment requires in-office administration and monitoring. Meadowlark Mind & Body follows applicable Spravato REMS safety requirements.
In select cases, off-label compounded ketamine may be considered as part of a carefully monitored treatment plan. Compounded ketamine is not FDA-approved for the treatment of depression, anxiety, or other psychiatric conditions and is not appropriate for every patient. Risks, benefits, alternatives, limitations, abuse potential, dissociation, sedation, blood pressure effects, safety concerns, and monitoring expectations are reviewed before treatment. Patients experiencing suicidal intent, psychosis, mania, severe intoxication, substance misuse concerns, or medical instability may require a higher level of care or emergency evaluation.